Modulation of in vivo glutamine and glycine levels in the treatment of autism
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Mar 26, 2002
Grant Date -
Nov 22, 2001
app pub date -
Dec 5, 2000
filing date -
Dec 8, 1999
priority date (Note) -
Expired
status (Latency Note)
Importance
Abstract
A method of treating autism in a patient. The method includes administering to the patient an effective amount of a glutamine level reducing agent, a glycine level reducing agent or combinations thereof. Representative glutamine level reducing agents are phenylbutyrate and phenylacetate, and a representative glycine level reducing agent is sodium benzoate. Optionally, an N-methyl-D-aspartate receptor antagonist can also be administered to the patient. A representative N-methyl-D-aspartate receptor antagonist is dextromethorphan.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully